Lupus Trial, Recruiting NCT05714930 Sponsor: Heinrich-Heine University, Duesseldorf Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT05714930
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoimmune disease) based on recognised medical criteria
  • You are at least 18 years old
  • Your SLE is not currently in full remission — meaning your disease is still showing some level of activity, whether through test scores, needing more than a low dose of steroid medication (above 5mg prednisone or equivalent per day), or your doctor rating your disease activity at a certain level
  • You can speak and understand German fluently
  • You are willing and able to give written consent to take part

Who may not be able to join:

  • You are already taking part in another clinical trial that involves a treatment or intervention
  • You have a life-threatening form of SLE that requires intensive care treatment
  • You have another serious, life-threatening illness unrelated to SLE
  • You have an active cancer diagnosis
  • You have an ongoing infection (either short-term or long-term) that would make it unsafe to increase immune-suppressing treatment
  • You have any other disease or condition that the trial doctor believes would make participation unsafe or affect the trial results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthias Schneider, MD, Heinrich-Heine University, Duesseldorf

Phone: 0211 81 17817

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Heinrich-Heine University, Duesseldorf
Registry
ClinicalTrials.gov
Start date
12 December 2023
Est. completion
31 December 2029

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Damage accrual

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov